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Tatiana Kuznetsova, Christian Torp-Pedersen, Lars Lind, Hans Ibsen, Yutaka Imai, Jiguang Wang, Edgardo Sandoya, Eoin O’Brien, Jan A Staessen, 
on behalf of the International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators†
Summary 
Background Few studies have formally compared the predictive value of the blood pressure at night over and beyond 
the daytime value. We investigated the prognostic signifi cance of the ambulatory blood pressure during night and day 
and of the night-to-day blood pressure ratio. 
Methods We did 24-h blood pressure monitoring in 7458 people (mean age 56·8 years [SD 13·9]) enrolled in 
prospective population studies in Denmark, Belgium, Japan, Sweden, Uruguay, and China. We calculated 
multivariate-adjusted hazard ratios for daytime and night-time blood pressure and the systolic night-to-day ratio, 
while adjusting for cohort and cardiovascular risk factors. 
Findings Median follow-up was 9·6 years (5th to 95th percentile 2·5–13·7). Adjusted for daytime blood pressure, 
night-time blood pressure predicted total (n=983; p<0·0001), cardiovascular (n=387; p<0·01), and non-cardiovascular 
(n=560; p<0·001) mortality. Conversely, adjusted for night-time blood pressure, daytime blood pressure predicted 
only non-cardiovascular mortality (p<0·05), with lower blood pressure levels being associated with increased risk. 
Both daytime and night-time blood pressure consistently predicted all cardiovascular events (n=943; p<0·05) and 
stroke (n=420; p<0·01). Adjusted for night-time blood pressure, daytime blood pressure lost prognostic signifi cance 
only for cardiac events (n=525; p≥0·07). Adjusted for the 24-h blood pressure, night-to-day ratio predicted mortality, 
but not fatal combined with non-fatal events. Antihypertensive drug treatment removed the signifi cant association 
between cardiovascular events and the daytime blood pressure. Participants with systolic night-to-day ratio value of 
1 or more were older, at higher risk of death, and died at an older age than those whose night-to-day ratio was normal 
(≥0·80 to <0·90). 
Interpretation In contrast to commonly held views, daytime blood pressure adjusted for night-time blood pressure 
predicts fatal combined with non-fatal cardiovascular events, except in treated patients, in whom antihypertensive 
drugs might reduce blood pressure during the day, but not at night. The increased mortality in patients with higher 
night-time than daytime blood pressure probably indicates reverse causality. Our fi ndings support recording the 
ambulatory blood pressure during the whole day.
Introduction 
In 1988, O’Brien and colleagues1 reported for the fi rst 
time that an abnormal circadian blood-pressure profi le 
with a less marked decrease in night-time blood pressure 
led to an increased risk of stroke. Subsequent studies of 
populations2–5 and hypertensive cohorts6–12 generally 
corroborated that a raised nocturnal blood pressure 
predicted a higher rate of cardiovascular complications. 
Despite the apparent agreement between these 
previously published large-scale studies,2–12 several 
potential limitations need further clarifi cation of the 
prognostic accuracy of day versus night ambulatory 
blood pressure. Many studies considered only fatal 
outcomes2,3,10,11 or did not have the power to study 
cause-specifi c cardiovascular endpoints.2,3,5,9 Investigators 
dichotomised the night-to-day blood pressure ratio, and 
applied diff erent defi nitions of dipping status or 
diff erent daytime and night-time intervals. Few reports 
formally compared the predictive value of the blood 
pressure at night over and beyond the daytime value. 
Finally, in cohorts of patients with hypertension, 
antihypertensive drug treatment attenuated the 
association between outcome and blood pressure.7 
An international consortium constructed a database 
of prospective population studies with the goal to 
advance research on the prognostic accuracy of the 
ambulatory blood pressure.13,14 We aimed to report risk 
estimates that were independently associated with the 
daytime and night-time blood pressures. Additionally, 
we investigated in categorical and continuous analyses 
whether the night-to-day blood pressure ratio contained 
any prognostic information over and beyond the 24-h 
blood pressure. 
Methods 
Study population 
We constructed the International Database on 
Ambulatory blood pressure monitoring in relation to 
Cardiovascular Outcomes (IDACO).13,14 Studies were 
eligible for inclusion if they included a random 
population sample, if information about the conventional 
and ambulatory blood pressures and cardiovascular risk 
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factors were available at baseline, and if the subsequent 
follow-up included fatal and non-fatal outcomes. We did 
an electronic search of studies written in English, using 
the search terms “ambulatory blood pressure 
monitoring” and “population”, which identifi ed 
11 studies.2–5,15–21 We excluded fi ve because at the time of 
writing they were still in progress15,18,21 or had not yet 
been organised,20 or because follow-up did not include 
non-fatal events.5 
For our analysis, we included 2311 residents from 
Copenhagen, Denmark;3 2542 from Noorderkempen, 
Belgium;16 1535 from Ohasama, Japan;2 1859 from 
Montevideo, Uruguay;19 360 from the JingNing county, 
China;17 and 1221 70-year-old men from Uppsala, Sweden.4 
All studies included in IDACO received ethical 
approval2–4,16,17,19 and have previously been described in 
detail.2–4,16,17,19 All participants provided informed written 
consent. Of the 9828 participants, we excluded 2370 (24%), 
because they were younger than 18 years old at enrolment 
(n=15), because their conventional blood pressure had 
not been measured (n=217), or because their daytime 
(n=229) or night-time (n=1909) blood pressure had not 
been registered or were averages of fewer than ten 
daytime or fi ve night-time readings. Thus, 7458 people 
were included in the analysis.
Procedures
Trained observers measured the conventional blood 
pressure with a mercury sphygmomanometer3,4,16,17 or 
with validated auscultatory22,23 (USM-700F, UEDA 
Electronic Works, Tokyo, Japan)2 or oscillometric 
(OMRON HEM-705CP, Omron Corporation, Tokyo, 
Japan)19 devices, using the appropriate cuff  size, with 
participants in the sitting2,3,16,17,19 or supine4 position. 
Conventional blood pressure was the average of two 
consecutive readings obtained either at the persons’ 
home16,17,19 or at an examination centre.2–4 We defi ned 
hypertension as a conventional blood pressure of at least 
140 mm Hg systolic or 90 mm Hg diastolic, or as use of 
antihypertensive drugs. 
We initiated portable blood-pressure monitors to obtain 
readings every 30-min throughout the whole day2 or at 
intervals ranging from 15 min3 to 30 min4 during daytime, 
and from 30 min3 to 60 min4 at night. The devices 
implemented an auscultatory algorithm (Accutracker II, 
Suntech Medical Instruments Inc, Morrisville, USA24) in 
Uppsala4 or an oscillometric technique (SpaceLabs 90202 
and 90207, SpaceLabs Inc, Redmond, USA25) in 
Noorderkempen,16 Montevideo,19 and JingNing.17 The 
Takeda TM-2421 recorders (A&D, Tokyo, Japan26) used in 
Copenhagen3 and the ABPM-630 devices (Nippon Colin, 
Komaki, Japan27) used in Ohasama2 implemented both 
techniques, but we only analysed the oscillometric 
readings. 
The same SAS macro processed all ambulatory 
recordings, which generally stayed unedited. The 
Ohasama recordings were edited sparsely according to 
previously published criteria.28 When accounting for the 
daily pattern of activities of the participants, we defi ned 
daytime as the interval ranging from 1000 h to 2000 h in 
people from Europe3,4,16 and South America,19 and from 
0800 h to 1800 h in those from Asia.2,17 The corresponding 
night-time intervals ranged from midnight to 0600 h3,4,16,19 
and from 2200 h to 0400 h.2,17 These fi xed intervals 
eliminate the transition periods in the morning and 
evening when blood pressure changes rapidly, resulting 
in daytime and night-time blood pressure levels that are 
within 1–2 mm Hg of the awake and asleep levels.17,29 We 
weighted the individual means of the ambulatory 
blood pressure by the interval between readings. 
In categorical analyses, we classifi ed the participants 
according to the night-to-day ratio of systolic blood 
pressure because mean age was 56·8 years and in adults 
older than 50 years systolic rather than diastolic blood 
pressure is the predominant risk factor.30 Moreover, we 
previously showed that the systolic night-to-day ratio, but 
not the diastolic night-to-day ratio, was similar in 
auscultatory and oscillometric recordings.31 We also 
avoided divergent classifi cation of participants on the 
basis of systolic or diastolic blood pressure or both, using 
the systolic night-to-day ratio. Normal dipping, used as the 
reference group in categorical analyses, was a night-to-day 
ratio ranging from less than 0·90 to 0·80 inclusive. We 
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Extreme Normal Decreased Reverse 
Limits <0·80 ≥0·80 to <0·90 ≥0·90 to <1·00 ≥1·00 
Total 1513 3754 1754 437
European 987 (65%)† 2299 (61%) 894 (51%)§ 178 (41%)§ 
Asian 317 (21%) 776 (21%) 433 (24%)‡ 140 (32%)§ 
South American 209 (14%)‡ 679 (18%) 427 (24%)§ 119 (27%)§ 
Women 670 (44%) 1728 (46%) 832 (47%) 186 (43%) 
Antihypertensive treatment 336 (22%)† 698 (19%) 440 (25%)§ 163 (37%)§ 
Smokers 456 (30%) 1150 (31%) 455 (26%)‡ 111 (25%)* 
Alcohol drinkers 809 (54%)‡ 1812 (48%) 755 (43%)‡ 164 (38%)§ 
Diabetes mellitus 99 (7%) 259 (7%) 131 (8%) 54 (12%) § 
Cardiovascular disorder 138 (9%)* 273 (7%) 155 (9%)* 60 (14%)§ 
Age (years) 58·6  (12·5)§ 55·2 (13·8) 57·1 (14·5)§ 62·9 (14·0)§ 
Body-mass index (kg/m²) 25·6 (4·0) 25·5 (4·0) 25·6 (4·4) 25·4 (4·7) 
Conventional blood pressure (mm Hg) 
Systolic 134·0 (19·4)§ 131·1 (20·6) 132·7 (21·8)† 136·5 (22·5)§ 
Diastolic 80·9 (10·9)† 79·9 (11·6) 79·7 (12·1) 79·4 (12·3) 
Ambulatory blood pressure (mm Hg) 
24-h systolic 124·8 (12·6)† 123·7 (14·1) 125·6 (15·5)§ 131·0 (17·9)§ 
24-h diastolic 73·7 (7·6) 73·7 (8·4) 74·6 (9·2)‡ 75·4 (9·7)§ 
Night-time systolic 104·0 (10·7)§ 111·1 (12·9) 120·2 (15·1)§ 134·8 (19·8)§ 
Night-time diastolic 60·1 (6·9)§ 64·1 (8·2) 68·9 (9·5)§ 74·1 (10·8)§ 
Daytime systolic 137·3 (14·4)§ 130·7 (15·0) 128·1 (15·8)§ 126·8 (16·7)§ 
Daytime diastolic 81·7 (8·8)§ 79·0 (9·0) 77·4 (9·6)§ 75·3 (10·1)§ 
Serum cholesterol (mmol/L) 5·82 (1·15)† 5·72 (1·13) 5·64 (1·14)* 5·48 (1·12)§ 
Data are number (%) or mean (SD). p values for the diff erences with normal: *p<0·05, †p<0·01, ‡p<0·001, §p<0·0001. 
Table 1: Baseline characteristics of participants by categories of the night-to-day ratio of systolic blood 
pressure 
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labelled the other categories of dipping status as extreme 
(<0·80),8 decreased (≥0·90–<1·00), and reverse (≥1·00).8 
In all cohorts, we administered a questionnaire to 
obtain baseline information about every participant’s 
medical history, intake of drugs, and smoking and 
drinking habits. Body-mass index was body weight (kg) 
divided by height (m) squared. Serum cholesterol and 
blood glucose concentrations were recorded by automated 
enzymatic methods. Diabetes mellitus was a self-reported 
diagnosis, or a fasting blood glucose concentration of at 
least 7·0 mmol/L or a random blood glucose concentration 
of 11·1 mmol/L,32 or use of antidiabetic drugs. 
We ascertained vital status and incidence of fatal and 
non-fatal diseases from the appropriate sources in every 
country, as described in detail in previous 
publications.4,33–35 Fatal and non-fatal stroke did not 
include transient ischaemic attacks. Coronary events 
encompassed death from ischaemic heart disease, 
sudden death, non-fatal myocardial infarction, and 
coronary revascularisation. Cardiac events consisted of 
coronary endpoints and fatal and non-fatal heart failure. 
In the Swedish cohort, the diagnosis of heart failure 
required admission to hospital. In the other 
cohorts,17,19,33–35 heart failure was either a clinical 
diagnosis or the diagnosis on the death certifi cate, but 
all cases were validated against hospital fi les or the 
records held by family doctors. The composite 
cardiovascular endpoint included all these endpoints 
plus cardiovascular mortality. In all outcome analyses 
we considered only the fi rst event within every 
category. 
Statistical analysis 
For database management and statistical analysis, we 
used SAS software (version 9.1.3; SAS Institute, Cary NC, 
USA). For comparison of means we applied the Z test for 
large samples and for comparison of proportions we 
applied the χ²-statistic. After stratifi cation for cohort and 
sex, we interpolated missing values of body-mass index 
(n=10) and total serum cholesterol (n=52) from the 
regression slope on age. In participants with unknown 
drinking (n=34) or smoking habits (n=445 in Swedish 
men4 and 167 in other cohorts17,19,33–35), we set the design 
variable to the cohort-specifi c and sex-specifi c mean of 
the codes (0,1). Statistical signifi cance was an α-level of 
0·05 on two-sided tests. 
We used Cox regression to compute standardised 
hazard ratios. We checked the proportional hazards 
assumption by the Kolmogorov-type supremum test, as 
implemented in the PROC PHREG procedure of the 
SAS package and by testing the interaction terms 
between follow-up duration and either blood pressure 
or the night-to-day blood pressure ratio. We fi rst plotted 
incidence rates by quintiles of the blood pressure 
distributions, while standardising by the direct method 
for cohort, sex, and age (≤40, 40–60, and ≥60 years). In 
adjusted models, we treated age as a continuous variable 
and additionally accounted for body-mass index, 
smoking and drinking, serum total cholesterol, history 
of cardiovascular disease, diabetes mellitus, and 
treatment with antihypertensive drugs. Fully adjusted 
models for the daytime blood pressure additionally 
included the corresponding night-time blood pressure, 
and vice versa, and for the night-to-day ratio they 
additionally included the 24-h systolic blood pressure. 
We adjusted for cohort by introducing fi ve design 
variables in the Cox models. We analysed the 
night-to-day blood pressure ratios both as continuous 
and categorical variables. In the categorical analyses, 
we plotted Kaplan-Meier survival function estimates 
according to present recommendations.36 We tested 
heterogeneity in the hazard ratios across subgroups by 
introduction of the appropriate interaction term in the 
Cox model. 
Role of the funding source 
The sponsor of the study had no role in study design, 
data extraction, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had responsibility 
for the decision to submit for publication. 
Total Non-cardiovascular Cardiovascular 
Number of deaths (%) 983 (13%) 560 (8%) 387 (5%)
Daytime blood pressure 
Systolic
  Adjusted 1·09 (1·02–1·16)* 0·96 (0·88–1·05) 1·29 (1·17–1·42)§ 
  Fully adjusted 0·94 (0·87–1·03) 0·84 (0·75–0·94)† 1·11 (0·98–1·27) 
Diastolic
  Adjusted 1·06 (0·99–1·14) 0·97 (0·89–1·06) 1·24 (1·12–1·37)§ 
  Fully adjusted 0·94 (0·87–1·03) 0·88 (0·79–0·98)* 1·07 (0·94–1·22) 
Night-time blood pressure 
Systolic
  Adjusted 1·18 (1·11–1·25)§ 1·10 (1·01–1·19)* 1·29 (1·19–1·41)§
  Fully adjusted 1·22 (1·13–1·31)§ 1·21 (1·10–1·33)‡ 1·22 (1·09–1·36)‡
Diastolic
  Adjusted 1·16 (1·09–1·24)§ 1·09 (1·00–1·19)* 1·29 (1·18–1·42)§
  Fully adjusted 1·20 (1·11–1·30)§ 1·18 (1·06–1·31)† 1·24 (1·10–1·40)‡
Night-to-day blood pressure ratio 
Systolic
  Adjusted 1·15 (1·09–1·21)§ 1·16 (1·08–1·24)§ 1·13 (1·04–1·23)†
  Fully adjusted 1·13 (1·07–1·19)§ 1·16 (1·08–1·25)§ 1·08 (0·99–1·17)
Diastolic
  Adjusted 1·13 (1·07–1·20)§ 1·14 (1·05–1·23)† 1·13 (1·03–1·24)†
  Fully adjusted 1·12 (1·06–1·19)‡ 1·14 (1·05–1·23)† 1·10 (1·00–1·21)*
Data are number (%) or standardised hazard ratios (95% CI), which express the risk per SD increase in the blood-
pressure variables. Systolic/diastolic SDs were 15·52/9·33 mm Hg and 15·53/9·25 mm Hg for the day and night blood 
pressures and 0·08/0·09 for the night-to-day blood pressure ratio. The cause of death was unknown in 36 cases. All 
hazard ratios were adjusted for cohort, sex, age, body-mass index, smoking and drinking, serum cholesterol, history of 
cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. In fully adjusted models, the daytime 
blood pressure was additionally adjusted for the night-time blood pressure (and vice versa), and the night-to-day ratio 
was additionally adjusted for the 24-h blood pressure. *p<0·05. †p<0·01. ‡p<0·001. §p<0·0001. 
Table 2: Adjusted standardised hazard ratios for mortality
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Results 
The study population consisted of 4358 (58%) people 
from Europe, 1666 (22%) from Asia, and 1434 (19%) from 
South America. 3416 (46%) of the participants were 
women, and 3436 (46%) had hypertension on 
conventional blood pressure measurement, 1637 (48%) 
of whom were taking drugs to lower their blood pressure. 
Mean age was 56·8 (SD 13·9) years. The mean 
conventional blood pressure was 132·4 (20·8) mm Hg 
systolic and 80·1 (11·6) mm Hg diastolic. For the 24-h 
blood pressure, these values were 124·8 (14·5) mm Hg 
and 74·0 (8·5) mm Hg, respectively. At enrolment, 
2172 (29%) participants were current smokers and 
3540 (48%) reported drinking alcohol. Table 1 shows the 
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Figure 1: Incidence of mortality (A, B) and cardiovascular events (C, D) by quintiles of the distributions of the daytime and night-time blood pressures in 7458 participants 
CV=cardiovascular. Incidence rates were standardised for cohort, sex, and age by the direct method. Mortality rates are plotted separately for total, non-cardiovascular, and cardiovascular deaths. 
Cardiovascular events include fatal and non-fatal endpoints and are given for all cardiovascular events combined, stroke, and cardiac events. The number of endpoints contributing to the rates is shown. 
All Stroke Cardiac Coronary 
Number of events (%) 943 (13%) 420 (6%) 525 (7%) 390 (5%)
Daytime blood pressure 
Systolic
  Adjusted 1·33 (1·25–1·42)§ 1·47 (1·34–1·62)§ 1·25 (1·15–1·36)§ 1·23 (1·11–1·36)§ 
  Fully adjusted 1·16 (1·07–1·26)‡ 1·27 (1·13–1·43)‡ 1·11 (0·99–1·24) 1·19 (1·04–1·36)* 
Diastolic
  Adjusted 1·25 (1·17–1·33)§ 1·39 (1·26–1·53)§ 1·15 (1·05–1·25)† 1·17 (1·06–1·30)† 
  Fully adjusted 1·11 (1·02–1·20)* 1·21 (1·07–1·37)† 1·04 (0·93–1·17) 1·11 (0·98–1·27) 
Night-time blood pressure 
Systolic
  Adjusted 1·31 (1·24–1·38)§ 1·40 (1·29–1·51)§ 1·24 (1·16–1·34)§ 1·16 (1·06–1·26)† 
  Fully adjusted 1·21 (1·12–1·30)§ 1·23 (1·11–1·37)‡ 1·17 (1·06–1·29)† 1·05 (0·93–1·18) 
Diastolic
  Adjusted 1·28 (1·20–1·36)§ 1·39 (1·26–1·52)§ 1·18 (1·09–1·28)§ 1·15 (1·05–1·27)† 
  Fully adjusted 1·20 (1·11–1·30)§ 1·24 (1·10–1·39)‡ 1·15 (1·04–1·28)† 1·08 (0·96–1·22) 
Night-to-day blood pressure ratio 
Systolic
  Adjusted 1·11 (1·05–1·17)‡ 1·09 (1·00–1·19)* 1·11 (1·02–1·19)* 1·01 (0·92–1·11) 
  Fully adjusted 1·05 (0·98–1·11) 1·02 (0·94–1·11) 1·05 (0·97–1·14) 0·97 (0·89–1·07) 
Diastolic
  Adjusted 1·09 (1·02–1·16)† 1·07 (0·97–1·17) 1·09 (1·00–1·18)* 1·02 (0·93–1·13) 
  Fully adjusted 1·07 (1·00–1·13)* 1·04 (0·95–1·14) 1·07 (0·98–1·16) 1·00 (0·91–1·11) 
Data are number (%) or standardised hazard ratios (95% CI). See table 2 legend for details of standardised hazard ratios. *p<0·05. †p<0·01. ‡p<0·001. §p<0·0001. 
Table 3: Adjusted standardised hazard ratios for combined, fatal, and non-fatal cardiovascular endpoints  
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baseline characteristics by category of the systolic 
night-to-day ratio. Across the four groups, all 
characteristics diff ered signifi cantly (table 1) with the 
exception of the proportion of women (p=0·16), 
body-mass index (p=0·08), and the conventional diastolic 
blood pressure (p=0·88). Table 1 also shows signifi cance 
levels for the comparison of the night-to-day ratio 
categories with the subgroup with a normal night-to-day 
ratio (≥0·80 to <0·90). Participants with a night-to-day 
ratio of 1·00 or higher were older, were more likely to 
come from Asia and South America, and have a history 
of diabetes mellitus or previous cardiovascular compli-
cations, than those with a normal night-to-day ratio. 
In the overall study population, the median follow-up 
was 9·6 years (5th to 95th percentile 2·5–13·7). Across 
cohorts, median follow-up ranged from 2·5 years 
(2·3–2·6) in JingNing to 13·1 years (1·1–15·7) in 
Noorderkempen. 983 participants died (14·1 per 
1000 person-years) and 943 had a fatal or non-fatal 
cardiovascular complication (13·6 per 1000 person-years). 
There were more non-cardiovascular than cardiovascular 
deaths (table 2). Of the cause-specifi c fi rst cardiovascular 
events, 51 were fatal strokes and 369 were non-fatal 
strokes. Cardiac events consisted of 146 fatal and 
379 non-fatal events, including 65 fatal and 186 non-fatal 
cases of acute myocardial infarction, 30 deaths from 
ischaemic heart disease, 30 sudden deaths, 21 fatal and 
142 non-fatal cases of heart failure, and 51 cases of 
surgical or percutaneous coronary revascularisation. Of 
the coronary revascularisation procedures, 18 took place 
in Noorderkempen, one in Copenhagen, and 32 in 
Montevideo. 
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Figure 2: Cumulative incidence of age at death by category of the 
night-to-day ratio of systolic blood pressure 
The p value refers to the diff erence between people classifi ed as reverse and 
normal dippers. 
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Figure 3: Kaplan-Meier survival function estimates for total mortality (A) and for all cardiovascular events (B) 
by category of the night-to-day ratio of systolic blood pressure 
CV=cardiovascular. p values are for trend across the four categories. Incidence was adjusted for cohort, sex, age, 
body-mass index, smoking and drinking, serum total cholesterol, history of cardiovascular disease, diabetes 
mellitus, and antihypertensive drug treatment. 
Extreme Normal Decreased Reverse 
Mortality 
Total
Deaths (%) 182 (12%) 418 (11%) 265 (15%) 118 (27%)
Hazard ratio 0·93 (0·78–1·11) referent 1·19 (1·02–1·39)* 1·56 (1·26–1·92)‡
Non-CV
Deaths (%) 106 (7%) 238 (6%) 150 (9%) 66 (15%) 
Hazard ratio 0·94 (0·75–1·19) referent 1·25 (1·01–1·54)* 1·66 (1·25–2·20)†
CV
Deaths (%) 73 (5%) 162 (4%) 102 (6%) 50 (11%)
Hazard ratio 0·97 (0·73–1·28) referent 1·08 (0·84–1·39) 1·45 (1·02–2·02)*
Fatal and non-fatal CV events 
All
Events (%) 178 (12%) 420 (11%) 237 (14%) 108 (25%) 
Hazard ratio 0·87 (0·73–1·04) referent 1·05 (0·88–1·23) 1·30 (1·04–1·62)*
Stroke
Events (%) 81 (5%) 178 (5%) 113 (6%) 48 (11%)
Hazard ratio 0·95 (0·73–1·24) referent 1·13 (0·89–1·44) 1·20 (0·87–1·67)
Cardiac
Events (%) 99 (7%) 244 (7%) 125 (7%) 57 (13%) 
Hazard ratio 0·84 (0·67–1·07) referent 0·97 (0·78–1·22) 1·31 (0·97–1·77)
Coronary
Events (%) 83 (6%) 185 (5%) 93 (5%) 29 (7%) 
Hazard ratio 0·92 (0·71–1·20) referent 0·99 (0·77–1·28) 0·92 (0·62–1·38)
CV=cardiovascular. Values for deaths and events are the number of participants, with the crude rate per 100 people 
given between parentheses. All hazard ratios express the risk versus normal (referent) and were adjusted for cohort, 
sex, age, body-mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes 
mellitus, antihypertensive drug treatment, and the 24-h blood pressure. *p<0·05. †p<0·001. ‡p<0·0001. 
Table 4: Adjusted hazard ratios (95% CI) associated with extreme, decreased, and reverse dipping 
versus normal dipping 
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Figure 1 shows the rates of mortality and cardiovascular 
events standardised by cohort, sex, and age. Table 2 
shows the multivariate-adjusted hazard ratios associated 
with every SD increase in the day and night blood 
pressures. The hazard ratios for the night-to-day ratios 
are shown in table 2 for mortality and in table 3 for fatal 
combined with non-fatal cardiovascular events.
In adjusted models, night-time blood pressure 
predicted all mortality outcomes, whereas daytime blood 
pressure predicted total and cardiovascular mortality, 
but not death from non-cardiovascular causes (table 2). 
In fully adjusted models, the night-time blood pressure 
was a signifi cant predictor of total, cardiovascular, and 
non-cardiovascular mortality. In contrast, in the presence 
of night-time blood pressure, the daytime blood pressure 
was not signifi cant for total and cardiovascular mortality, 
but was signifi cant for non-cardiovascular mortality 
(table 2), with higher levels being associated with lower 
relative risk. 
With adjustments applied for cohort and risk factors, 
the daytime and night-time systolic and diastolic blood 
pressures consistently predicted cardiovascular, cardiac, 
and coronary events, and fatal and non-fatal stroke 
(table 3). In fully adjusted models, with correction for 
night-time blood pressure, the systolic daytime blood 
pressure lost its prognostic signifi cance for cardiac 
events (hazard ratio 1·11; p=0·07), whereas the diastolic 
daytime blood pressure became non-signifi cant for 
cardiac (1·04; p=0·45) and coronary (1·11; p=0·10) 
events (table 3). When adjusted for daytime blood 
pressure, the systolic and diastolic night-time levels no 
longer predicted coronary events (1·05; p=0·43 and 
1·08; p=0·21, respectively). 
In continuous analyses, the systolic and diastolic 
night-to-day ratios signifi cantly predicted total, 
non-cardiovascular, and cardiovascular mortality in 
models adjusted for cohort and risk factors (table 2). 
This fi nding was also noted in fully adjusted models, 
which were additionally adjusted for 24-h blood pressure 
(table 2). The only exception was the fully adjusted 
association of cardiovascular mortality with the systolic 
night-to-day ratio (p=0·10). In contrast with mortality, 
the systolic and diastolic night-to-day ratios were not 
consistent predictors of fatal combined with non-fatal 
events (table 3). In fully adjusted models, the systolic 
night-to-day ratio was not signifi cant (table 3) for all 
combined fatal and non-fatal outcomes investigated. 
The diastolic night-to-day ratio was only a signifi cant 
predictor of all cardiovascular outcomes (p=0·04), but 
not of other combined fatal and non-fatal events 
(table 3). 
Participants with higher night-time than daytime blood 
pressure were not only older at enrolment (table 1), but 
were also older when they died than were those with a 
normal night-to-day ratio (78·2 years vs 74·1 years; 
p<0·0001; fi gure 2). Both cardiovascular (78·9 years vs 
75·9 years; p=0·002) and non-cardiovascular (77·5 years 
vs 73·6 years; p=0·001) mortality contributed to this 
fi nding. 
Figure 3 shows Kaplan-Meier survival function 
estimates for total mortality and the composite 
cardiovascular endpoint by category of the systolic 
night-to-day ratio. With adjustments applied for cohort, 
cardiovascular risk factors, and the 24-h blood pressure, 
participants with higher night-time than daytime blood 
pressure or a less pronounced dip in blood pressure were 
associated with higher rates of total mortality and 
cardiovascular events than were those whose night-to-day 
blood pressure ratio was normal or extreme (p<0·0001). 
Table 4 provides the number of events per dipping class. 
Participants with higher night-time than daytime blood 
pressure had a signifi cantly higher risk of death from any 
cause and more fatal and non-fatal cardiovascular 
complications than did those with a normal night-to-day 
ratio (table 4). 
In sensitivity analyses involving total mortality and the 
composite of all fatal and non-fatal cardiovascular 
endpoints in relation to the daytime and night-time systolic 
blood pressure and the systolic night-to-day ratio, we 
stratifi ed according to sex, median age (60 years), history of 
At risk Events Daytime Night-time Night-to-day 
ratio
Total mortality 
All participants 7458 983 0·94 (0·87–1·03) 1·22 (1·13–1·31)§ 1·13 (1·07–1·19)§
Women 3416 (46%) 267 (27%) 0·97 (0·82–1·15) 1·35 (1·15–1·58)‡  1·16 (1·04–1·30)†
Men 4042 (54%) 716 (73%) 0·93 (0·84–1·02) 1·19 (1·09–1·29)§  1·12 (1·05–1·19)‡
<60 years 3756 (50%) 115 (12%) 1·12 (0·83–1·51) 1·20 (0·89–1·61) 1·06 (0·86–1·31)
≥60 years 3702 (50%) 868 (88%) 0·93 (0·85–1·02) 1·22 (1·13–1·31)§ 1·13 (1·07–1·20)§
No history of CVD 6832 (92%) 787 (80%) 0·97 (0·88–1·06) 1·22 (1·12–1·32)§ 1·12 (1·05–1·19)‡
History of CVD 626 (8%) 196 (20%) 0·89 (0·79–1·07) 1·23 (1·03–1·46)* 1·15 (1·02–1·31)*
Untreated 5821 (78%) 598 (61%) 0·98 (0·87–1·09) 1·20 (1·09–1·32)‡ 1·11 (1·03–1·19)†
Treated 1637 (22%) 384 (39%) 0·89 (0·78–1·01) 1·24 (1·11–1·38)‡ 1·16 (1·06–1·26)‡
Normotensive 4022 (54%) 315 (32%) 1·03 (0·86–1·24) 1·23 (1·04–1·44)* 1·09 (0·98–1·21)
Hypertensive 3436 (46%) 668 (68%) 0·91 (0·83–1·01) 1·22 (1·12–1·32)§ 1·14 (1·07–1·22)§
All cardiovascular events 
All participants 7458 943 1·16 (1·07–1·26)‡ 1·21 (1·12–1·30)§ 1·05 (0·98–1·11)
Women 3416 (46%) 255 (27%) 1·21 (1·02–1·44)* 1·38 (1·18–1·63)§  1·09 (0·97–1·23)
Men 4042 (54%) 688 (73%) 1·12 (1·02–1·23)* 1·18 (1·09–1·28)§  1·05 (0·98–1·12)
<60 years 3756 (50%) 139 (15%) 1·55 (1·21–1·99)‡ 1·22 (0·95–1·58) 0·94 (0·78–1·14)
≥60 years 3702 (50%) 804 (85%) 1·11 (1·02–1·21)* 1·21 (1·13–1·31)§ 1·07 (1·00–1·13)*
No history of CVD 6832 (92%) 745 (79%) 1·19 (1·08–1·30)‡ 1·22 (1·13–1·32)§ 1·05 (0·98–1·11)
History of CVD 626 (8%) 198 (21%) 1·09 (0·91–1·30) 1·14 (0·97–1·34) 1·04 (0·92–1·17)
Untreated 5821 (78%) 531 (56%) 1·30 (1·15–1·45)§ 1·15 (1·04–1·27)† 0·99 (0·91–1·07)
Treated 1637 (22%) 412 (44%) 1·01 (0·89–1·14) 1·27 (1·14–1·40)§ 1·12 (1·03–1·21)†
Normotensive 4022 (54%) 252 (27%) 1·32 (1·09–1·60)† 1·26 (1·05–1·51)† 1·01 (0·90–1·14)
Hypertensive 3436 (46%) 691 (73%) 1·11 (1·01–1·22)* 1·20 (1·11–1·30)§ 1·06 (0·99–1·13)
CVD=cardiovascular disease. Hypertension was a conventional blood pressure of at least 140 mm Hg systolic or 90 mm 
Hg diastolic or the use of antihypertensive drugs. p values for heterogeneity are reported in the text. All hazard ratios 
were adjusted as described in table 2 legend. *p<0·05. †p<0·01. ‡p<0·001. §p<0·0001. 
Table 5: Adjusted standardised hazard ratios (95% CI) for systolic blood pressure according to baseline 
characteristics 
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cardiovascular disease, treatment status, and the presence 
or absence of hypertension on conventional blood pressure 
measurement (table 5). The results across these strata were 
consistent with those in the whole study population with 
few exceptions. Women had higher hazard ratios for 
cardiovascular events in relation to the daytime blood 
pressure than did men (1·21 vs 1·12; p=0·06), and higher 
hazard ratios for both total mortality (1·35 vs 1·19; p=0·02) 
and cardiovascular events (1·38 vs 1·18; p=0·006) in 
relation to the night-time blood pressure. In participants 
younger than 60 years and in those who were untreated, 
the hazard ratios for cardiovascular events in relation to 
the daytime blood pressure were signifi cantly larger than 
were those in participants older than 60 years (1·55 vs 1·11; 
p=0·02) and in treated patients (1·30 vs 1·01; p=0·005). 
Figure 4 shows the multivariate-adjusted and independent 
associations of total mortality and all cardiovascular events 
with the daytime and night-time blood pressures by 
treatment status at enrolment. Addition of the interaction 
terms between treatment status and the daytime and 
night-time blood pressures to the models greatly improved 
the fi t (log likelihood ratio test p<0·0001). 
Sensitivity analyses, in which we excluded one cohort at 
a time, produced consistent results for total mortality and 
the combined cardiovascular endpoint in relation to the 
daytime and night-time systolic and diastolic blood 
pressures, and the systolic night-to-day ratio treated as a 
continuous variable (table 6).
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Figure 4: Absolute 10-year risk of death (A, B) or a cardiovascular event (C, D) in relation to systolic blood pressure by treatment status 
The night-time blood pressure is plotted along the x axis and the scale covers the 5th to 95th percentile interval. The daytime blood pressure is represented by four risk 
functions corresponding to levels of 100, 120, 140, and 160 mm Hg. Risk estimates were adjusted as in fi gure 3. np and ne indicate the number of participants at risk and 
the number of events. pd and pn denote the signifi cance of the independent contributions of the daytime and nighttime blood pressures. Addition of the interaction 
terms between the daytime and night-time blood pressures and treatment status greatly improved the fi t of the models (log likelihood ratio test; p<0·0001). 
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Discussion 
Our study has shown that the predictive accuracy of the 
daytime and night-time blood pressures and the 
night-to-day blood pressure ratio depended on the 
outcome under study. For fatal endpoints, the night-time 
blood pressure did better than the daytime blood 
pressure, and the night-to-day ratio predicted total, 
cardiovascular, and non-cardiovascular mortality. In 
contrast, for fatal combined with non-fatal outcomes, the 
daytime blood pressure did equally well as the night-time 
blood pressure, and the night-to-day ratio lost its 
prognostic accuracy in all participants and in those who 
were untreated. Our fi ndings suggest that a less 
pronounced dip in blood pressure might just be a marker 
of pre-existing or concurrent disease, leading to a lower 
daytime blood pressure, or might be the result of the 
intake of drugs to lower blood pressure during daytime. 
The worse prognosis for participants with higher 
night-time than daytime blood pressure was not 
associated with shorter life expectancy. 
We implemented a meta-analysis on the basis of data 
from individual participants. In terms of standardisation 
and quality, such an approach is better than undertaking 
a meta-analysis of aggregate data extracted from 
publications.37 As well as mortality, we investigated 
non-fatal events, which accrued during the long-term 
follow-up. We hold databases on several cohorts of 
patients with hypertension.7,10,38 We opted not to combine 
population samples and patient cohorts. In patients with 
hypertension, treatment to lower blood pressure might 
be a confounder with too large an eff ect to adjust for,13 
whereas in population studies, most hypertensive 
patients still remain untreated.39 Many researchers 
dichotomised dipping status with use of arbitrary 
thresholds. To compare our fi ndings with those in other 
studies, our report included outcome results according to 
category of dipping.8,31 However, in our main analyses, we 
treated the night-to-day blood pressure ratio as a 
continuous variable, adjusted for the 24-h blood pressure 
and other covariates. 
Our fi ndings challenge the commonly held view that 
night-time blood pressure has the greatest prognostic 
accuracy.2,4,7,8,10–12 One possible explanation is that 
antihypertensive drug treatment is a major confounder, 
and our results accord with this notion. Patients with 
more severe hypertension and those with a history of 
cardiovascular complications are more likely to be treated40 
and to be at higher risk than are other patients. 
Furthermore, patients with hypertension take their drugs 
during daytime, and the activity that lowers blood pressure 
probably weans off  at night. This mechanism predictably 
leads to a reduced daytime blood pressure, increased 
night-time blood pressure, and a decreased night-to-day 
blood pressure ratio. Addition to the Cox models of the 
interaction terms of the daytime and night-time blood 
pressures with treatment status substantially improved 
the fi t (fi gure 4). Reduction of the daytime blood pressure 
might explain why in treated patients, the fully adjusted 
hazard ratio of the daytime blood pressure was less than 
unity (p=0·07) for total mortality and far from 
signifi cant (p=0·87) for the composite of all fatal and 
non-fatal cardiovascular events. 
Several hypothetical mechanisms support the 
plausibility of an enhanced cardiovascular risk associated 
with an increased night-to-day ratio or raised night-time 
blood pressure, such as changes in the sympathetic 
modulation of the night-time blood pressure,41 disturbed 
barorefl ex sensitivity,42 sleep apnoea,43 or an increased salt 
sensitivity necessitating a high blood pressure at night to 
drive pressure natriuresis.44,45 Moreover, in terms of the 
measurement conditions, such as body position and 
physical activity, the night-time blood pressure is better 
standardised than is the daytime blood pressure. 
However, defi nitions of dipping categories depend on 
arbitrary thresholds. The use of systolic or diastolic blood 
pressure, or both, often produce inconsistent classifi cation 
of the same person. The night-to-day blood pressure ratio 
is subject to regression-to-the-mean.46 Dipping status has 
also a low reproducibility, with up to 40% of individuals 
from Europe47 and Asia48 changing status between repeat 
recordings. Correction for the diurnal variation in the 
hydrostatic gradient between the heart and the arm cuff  
did not improve the reproducibility of the night-to-day 
blood pressure ratio.49 We showed that the classifi cation 
according to dipping status is also vulnerable to 
antihypertensive drug treatment. 
The consensus view in the published work is that 
higher night-time than daytime blood pressure has the 
worst prognosis. In keeping with present opinion, we 
noted that such people were at a higher risk of death 
At risk Events Daytime Night-time Night-to-day 
ratio 
Total mortality 
All participants 7458 983 0·94 (0·87–1·03) 1·22 (1·13–1·31)§ 1·13 (1·07–1·19)§ 
Copenhagen 5321 (71%) 735 (75%) 0·92 (0·84–1·02) 1·22 (1·12–1·32)§ 1·13 (1·07–1·20)§ 
Ohasama 6141 (82%) 792 (81%) 0·97 (0·88–1·07) 1·19 (1·09–1·29)§ 1·10 (1·03–1·17)† 
Noorderkempen 6334 (85%) 847 (86%) 0·94 (0·86–1·02) 1·20 (1·12–1·30)§ 1·12 (1·06–1·19)§ 
Uppsala 6361 (85%) 685 (70%) 0·91 (0·82–1·02) 1·32 (1·19–1·46)§ 1·17 (1·09–1·26)§ 
Montevideo 6024 (81%) 887 (90%) 0·96 (0·87–1·04) 1·22 (1·13–1·31)§ 1·12 (1·06–1·19)§ 
JingNing 7109 (95%) 969 (99%) 0·95 (0·87–1·03) 1·20 (1·11–1·30)§ 1·12 (1·06–1·19)§ 
All cardiovascular events 
All participants 7458 943 1·16 (1·07–1·26)‡ 1·21 (1·12–1·30)§  1·05 (0·99–1·11) 
Copenhagen 5321 (71%) 691 (73%) 1·18 (1·08–1·30)‡ 1·16 (1·07–1·25)‡ 1·02 (0·96–1·08) 
Ohasama 6141 (82%) 794 (84%) 1·15 (1·05–1·26)† 1·20 (1·11–1·29)§ 1·04 (0·98–1·11) 
Noorderkempen 6334 (85%) 844 (90%) 1·14 (1·05–1·25)† 1·21 (1·12–1·30)§ 1·05 (1·00–1·12) 
Uppsala 6361 (85%) 629 (67%) 1·13 (1·01–1·26)* 1·36 (1·22–1·51)§ 1·11 (1·03–1·20)† 
Montevideo 6024 (81%) 822 (87%) 1·16 (1·06–1·26)† 1·21 (1·12–1·30)§ 1·05 (0·99–1·12) 
JingNing 7109 (95%) 935 (99%) 1·16 (1·07–1·26)‡ 1·20 (1·11–1·29)§ 1·05 (0·99–1·11) 
All hazard ratios were adjusted as described in table 2 legend. *p<0·05. †p<0·01. ‡p<0·001. §p<0·0001. 
Table 6: Adjusted standardised hazard ratios (95% CI) for systolic blood pressure excluding one cohort at 
a time
Articles
www.thelancet.com   Vol 370   October 6, 2007 1227
from all causes than were those with normal night-to-day 
ratio. However, the fully adjusted night-to-day ratio of 
systolic blood pressure was a weak predictor of fatal 
combined with non-fatal endpoints in continuous as well 
as categorical analyses. Both antihypertensive treatment 
and reverse causality might explain this discrepancy. 
Elderly patients (≥60 years) enrolled in the Systolic 
Hypertension in Europe trial7 had their ambulatory blood 
pressure measured after a 3-month run-in period on 
placebo. In patients subsequently randomly assigned to a 
placebo, the night-time systolic blood pressure was a 
better predictor of cardiovascular mortality and morbidity 
than was the daytime level. A 10% increase in the systolic 
night-to-day blood pressure ratio was also associated with 
a 41% increased cardiovascular risk, which was 
independent of the 24-h ambulatory blood pressure. 
Randomisation to active treatment attenuated these 
associations to non-signifi cance. 
Furthermore, in keeping with present IDACO results 
(table 1), people with higher night-time than daytime 
blood pressure in other studies were not only more 
frequently on antihypertensive drug treatment,8,11 but 
they were also older,8,11,50 and more likely to have a history 
of diabetes mellitus50 or previous cardiovascular disease8,50 
than were those whose night-to-day blood pressure ratio 
was normal. The night-to-day blood pressure ratio 
increases as age increases.31 In our analyses, people with 
higher night-time than daytime blood pressure died at an 
older age than did those with a night-time dip in blood 
pressure. Thus, higher night-time than daytime blood 
pressure might be a marker rather than a cause of a poor 
outcome. The fully-adjusted inverse associations between 
non-cardiovascular mortality and the daytime blood 
pressure in all people (table 2) and between total mortality 
and the daytime blood pressure in those who were 
untreated (fi gure 4) also lend support to the interpretation 
of reverse causality. 
Our study should be interpreted within the context of 
its potential limitations. First, the IDACO database 
consists of six population-based cohorts from three 
continents,2–4,16,17,19 but our results might not yet be 
generally applicable. Therefore, we are presently collecting 
outcome results in additional cohorts.15,18,19,21 Second, the 
six populations diff ered in anthropometric characteristics 
and lifestyle. Our analyses were multivariate-adjusted at 
the level of individual people, but we cannot exclude 
residual confounding. Sensitivity analyses showed that 
no one cohort had a disproportionately large eff ect. Third, 
in long-term international surveys, the defi nition of 
clinical events, such as coronary heart disease, is probably 
less precise than it is in short-term studies or randomised 
clinical trials, in which endpoints are obtained via a single 
channel of information. However, we used only hard 
outcomes, excluding transient ischaemic attacks and 
angina pectoris. Fourth, experts usually regard the asleep 
and awake blood pressures to be the best standards to 
analyse the diurnal blood pressure profi le.51,52 However, 
we previously noticed in people from Europe29 and China17 
that short fi xed clock-time intervals, which eliminate the 
transition periods in the morning and evening when 
blood pressure rapidly changes, result in daytime and 
night-time blood pressure means that are within 
1–2 mm Hg of the awake and asleep levels.17,29 Fifth, 
ambulatory blood pressure monitoring was not 
standardised across the six contributing studies in terms 
of device type and intervals between readings. However, 
we used the same programme to compute blood pressure 
means that were time weighted across cohorts. Finally, 
we could not adjust for antihypertensive drug treatment 
as a time-dependent covariate, because this information 
was only available for individuals in the Belgian 
cohort.16,34 However, the proportion of our patients on 
antihypertensive treatment at baseline was only 22%. 
During the course of follow-up, the proportion of treated 
patients, in view of the poor rates of treatment in the 
general population39 and the bad persistence of treatment 
in some clinical studies,40 should have been greatly lower 
than in cohorts of referred patients with hypertension, 
who were followed up at specialised hypertension 
centres6,38 or started on antihypertensive treatment at 
enrolment.9 
Our fi ndings have implications for clinical practice and 
research. The night-time blood pressure predicted 
mortality and non-fatal outcomes, irrespective of 
treatment status. The daytime blood pressure 
independently predicted the composite of all fatal and 
non-fatal cardiovascular events, especially in untreated 
participants. Our fi ndings therefore support recording 
the ambulatory blood pressure during the whole day. The 
proposed thresholds for the 24-h blood pressure,14 rather 
than the dipping pattern, should inform clinical decisions. 
Chronotherapy53 means timing the administration of 
antihypertensive drugs in such a way that the blood 
pressure is lowered over 24 h, while a normal night-to-day 
blood pressure ratio is preserved. However, there is no 
evidence supporting the effi  cacy of chronotherapy in 
terms of blood pressure control54 or outcome.47 
Furthermore, the classifi cation of patients according to 
the night-to-day blood pressure ratio greatly depends on 
arbitrary criteria, is poorly reproducible,47,48 and has a 
diff erent prognostic meaning according to the disease 
outcome under study, the prevailing 24-h blood pressure 
level, and treatment status. We would therefore 
recommend that in future publications any categorical 
representation of the night-to-day ratio be supported by 
continuous analyses adjusted for the 24-h blood pressure 
and be stratifi ed for treatment status.
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